[Natriuretic peptides as markers of development and prognosis of pulmonary hypertension severity in patients with chronic obstructive disease.]
Studied the diagnostic and prognostic significance of N-terminal precursor of natriuretic peptide С-type (NT-proCNP) and brain natriuretic peptide (NT-proBNP) in patients with COPD with pulmonary hypertension (PH). The study included 47 patients with COPD (II - IV degrees of severity, 2016 GOLD, men - 44, women -3, mean age 59,3±9.12 years, disease duration of 13.7±5.93 years, the index of Smoking at 23.1±10,93 pack-years, BMI of 27.2±12,06 m/kg2.). Criteria of pulmonary hypertension on the basis of the doppler-echocardiography was an increase of pulmonary artery systolic pressure (PASP) > 40 mmHg alone. Depending on the presence and degree of enhancement PASP patients were divided into three groups: 1 - without pulmonary hypertension (PASP < 40 mmHg, n=168), 2 - moderate pulmonary hypertension (PASP 40 - 55 mmHg, n=101), 3-group with severe pulmonary hypertension (PASP > 55 mmHg, n=19). There was a statistically significant intergroup differences (p1-2 0,001, p 2-3 0,001, p1-3 < 0,001) values of NT-proCNP and NT-proBNP. There was a significant correlation relationship SDLA with the concentration of NT-proCNP (r=0,53, p<0,05) and NT-proBNP (r=0,67; p=0,05). A high diagnostic value of determination of NT-proCNP and NT-proBNP to predict the development and severity of PH in patients with COPD. Cox regression analysis showed that elevated levels of NT-proCNP and NT-proBNP in COPD patients of PH c are the predictors of hospital mortality.